LLY compared with DMAC: revenue, margins and what each company keeps, and the suppliers and customers both name

LLYELI Lilly & Co

Mkt capRevenueRevenue

DMACDiaMedica Therapeutics Inc.

Mkt capRevenueRevenue

Compare

LLYELI Lilly & Co

DMACDiaMedica Therapeutics Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

Q1 FY26±5.3%▲+9.80%×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

DMAC

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±15.9%▲+3.31%×0.21

May 7 '26±36.3%▲+0.15%×0.00

= impliedLLY realized, solidDMAC realized, hatchedOne scale, both sides: full bar = 37%× = |realized| ÷ impliedSource: market data

Q1 FY26

±22.1%

▲+1.96%

×0.09

Q3 FY25±19.8%▼−14.10%×0.71

LLYELI Lilly & Co

1,368.54▲+0.28%

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

DMACDiaMedica Therapeutics Inc.

9.32▲+3.10%

Regular sessionNov 6 '26

Mkt cap$487.5MRevenue—Revenue—

Compare

Regular sessionNov 6 '26

LLYELI Lilly & Co

DMACDiaMedica Therapeutics Inc.

1,368.54▲+0.28%

Price

9.32▲+3.10%

$1.2T

Mkt cap

$487.5M

Q3 FY26$24.4B

Revenue

—

FY25$65.2B

Revenue

—

LLY1,368.54▲+0.28%vsDMAC9.32▲+3.10%Regular sessionNov 6 '26